Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs INBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INBX Captures Overall Composite Edge (51.4 HOLD vs 45.3 HOLD), While RGNX Leads 5–1 on Growth & Valuation Pillars

INBX Overall Winner 6-Pillar Tally: RGNX 5 – 1 INBX Matrix Metrics: RGNX 3 – 5 INBX

As of Nov 16, 2026, Inhibrx Biosciences, Inc. (INBX) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (51.4/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while RGNX wins 5–1 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus INBX at $77.32 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: INBX earns the overall head-to-head edge with a stronger Unified Composite Score (51.4/100 HOLD vs. RGNX 45.3/100 HOLD) and 2.53β · 120% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs INBX
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
INBX NASDAQ Head-to-Head Winner
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.32
-7.18% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.53β · 120% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $85.65 · SMA50: $94.39

6-Pillar Scorecard Institutional Category Breakdown (RGNX 5 – 1 INBX)

Columns: Metric · RGNX · INBX
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.26x N/M
EV / Revenue 3.1x N/M
2. Growth & Scale RGNX
Revenue Growth (YoY) -69.2% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M N/A
Market Cap $500.9M $1.3B
3. Profitability & Quality INBX
Gross Margin -64.5% N/A
Operating Margin -120.4% 0.0%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -1773.6%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$132M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $48M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 116.5% (8th %ile)
Put/Call OI Skew N/A 0.71x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (3) vs INBX (5)
Institutional Metric RGNX INBX Criterion Row Edge
Market Capitalization
Scale
$500.9M $1.3B Larger Scale INBX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-69.2% -100.0% Higher Growth RGNX
Operating Margin (TTM)
Profitability
-120.4% 0.0% Higher Margin INBX
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin INBX
Return on Equity (ROE)
Capital Efficiency
-113.2% -1773.6% Higher ROE RGNX
52-Week Range Position
Momentum
19% ($5–$16) 20% ($57–$155) Stronger Trend INBX
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 2.53β · 120% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite INBX
Trailing 12M Revenue (USD)
Operating Scale
$154M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$132M ($48M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +21.8 pp
RGNX: +7.87% · INBX: -13.93%
3M Horizon INBX +14.23 pp
RGNX: -32.52% · INBX: -18.29%
6M Horizon RGNX +59.13 pp
RGNX: +32.21% · INBX: -26.92%
1Y Horizon INBX +39.43 pp
RGNX: -35.82% · INBX: +3.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue INBX Revenue RGNX Op. Margin INBX Op. Margin Margin Leader
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -12178.9% RGNX
FY2024 $80M $0M -280.0% -165724.0% RGNX
FY2025 $170M $0M -94.6% -10386.5% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 116.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact INBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
INBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs INBX Key Questions & Quantitative Answers

As of Nov 16, 2026, Inhibrx Biosciences, Inc. (INBX) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (51.4/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while RGNX wins 5–1 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus INBX at $77.32 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: INBX earns the overall head-to-head edge with a stronger Unified Composite Score (51.4/100 HOLD vs. RGNX 45.3/100 HOLD) and 2.53β · 120% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RGNX leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with INBX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while INBX shifted N/A. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INBX.

RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus INBX (-1773.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, INBX carries 116.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.53β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.